IDiyas

For the Inventor, By the Inventor

Somerville, MA, United States of America

Hakan Gunaydin

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 9.3

ph-index = 2

Forward Citations = 39(Granted Patents)


Location History:

  • Boston, MA (US) (2016 - 2019)
  • Somerville, MA (US) (2016 - 2024)

Company Filing History:

goldMedal10 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal3 out of 1,970 
 
Amgen Inc.
 patents
bronzeMedal2 out of 12 
 
Relay Therapeutics, Inc.
 patents
4. 1 out of 27 
 
D.e. Shaw Research, LLC
 patents
where one patent can have more than one assignee

Years Active: 2016-2025

where 'Filed Patents' based on already Granted Patents

15 patents (USPTO):
1. 12331056 - SHP2 phosphatase inhibitors and methods of use thereof (2025-06-17),
2. 12215116 - Arginase inhibitors and methods of use (2025-02-04),
3. 12084447 - SHP2 phosphatase inhibitors and methods of use thereof (2024-09-10),
4. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),
5. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-16),
6. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),
7. 10975084 - KDM5 inhibitors (2021-04-13),
8. 10689369 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2020-06-23),
9. 10584121 - Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof (2020-03-10),
10. 10344000 - Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-07-09),
11. 10287272 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2019-05-14),
12. 10221142 - Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-03-05),
13. 9663508 - Biaryl acyl-sulfonamide compounds as sodium channel inhibitors (2017-05-30),
14. 9505749 - Quinazolinone compounds and derivatives thereof (2016-11-29),
15. 9340549 - Oxazolidinone compounds and derivatives thereof (2016-05-17),

Sure, let's create an article about inventor Hakan Gunaydin:

Title: Innovator Spotlight: Hakan Gunaydin - Pioneering Pharmaceutical Breakthroughs

Introduction:

Hakan Gunaydin is a prolific inventor based in Somerville, MA, USA, known for his groundbreaking work in the pharmaceutical industry. With a total of 11 patents to his name, Gunaydin has been at the forefront of developing innovative solutions for treating complex diseases.

Latest Patents:

Gunaydin's latest patents showcase his expertise in developing cutting-edge pharmaceutical compounds. His patents include "Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof" and "Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof." These inventions aim to inhibit the LRRK2 kinase and have the potential to revolutionize the treatment of diseases like Parkinson's Disease.

Career Highlights:

Currently employed at Merck Sharp & Dohme Corporation, Gunaydin has been instrumental in driving innovation within the company. His work has not only led to the development of novel compounds but has also paved the way for future advancements in the pharmaceutical field.

Collaborations:

Gunaydin has collaborated with esteemed professionals in his field, including Blair T Lapointe and Peter H Fuller. Together, they have worked on various projects aimed at addressing unmet medical needs and improving patient outcomes.

Conclusion:

In conclusion, Hakan Gunaydin stands as a shining example of innovation in the pharmaceutical industry. His dedication to developing novel solutions for challenging diseases like Parkinson's Disease has earned him recognition as a leading figure in the field. Gunaydin's contributions continue to have a lasting impact on the healthcare landscape, offering hope for a better future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…